The Administration of Complement Component C9 Enhances the Survival of Neonatal Rats with Escherichia coli Sepsis1

No abstract is available for this paper.

• Publication year

  1997

• Venue

  Pediatric Research

• Publication date

  1997-07-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1203/00006450-199707000-00020PMID 9212048
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Supplemental Complement Component C9 Enhances the Capacity of Neonatal Serum to Kill Multiple Isolates of Pathogenic Escherichia coli

  1994cited by this paper
• Complement factor 9 deficiency in serum of human neonates.

  1992cited by this paper
• Bactericidal activity of C9-deficient human serum.

  1992cited by this paper
• Inefficient bacteriolysis of Escherichia coli by serum from human neonates.

  1992cited by this paper
• Complement: Clinical Aspects and Relevance to Disease

  1991cited by this paper
• Bacterial killing and inhibition of inner membrane activity by C5b-9 complexes as a function of the sequential addition of C9 to C5b-8 sites.

  1990cited by this paper
• Preparation of polyclonal antibodies.

  1990cited by this paper
• Maternofetal Transfer of IgG Anti-Escherichia coli Antibodies with Enhanced Avidity and Opsonic Activity in Very Premature Neonates

  1990cited by this paper
• Purification of C8 and C9 from rat serum.

  1990cited by this paper
• Inherited complement deficiency states: implications for immunity and immunological disease

  1990cited by this paper
• Comparison of channels formed by poly C9, C5b-8 and the membrane attack complex of complement.

  1990cited by this paper
• The membrane attack pathway of complement.

  1989cited by this paper
• Inherited deficiency of ninth component of complement: an increased risk of meningococcal meningitis.

  1989cited by this paper
• The molecular mechanism of complement C9 insertion and polymerisation in biological membranes.

  1989cited by this paper
• Membrane attack complex proteins C5b-6, C7, C8, and C9 of human complement.

  1988cited by this paper
• Sequence from picomole quantities of proteins electroblotted onto polyvinylidene difluoride membranes.

  1987cited by this paper
• The membrane attack complex of complement.

  1986cited by this paper
• Multimeric complement component C9 is necessary for killing of Escherichia coli J5 by terminal attack complex C5b-9.

  1985cited by this paper
• Measurement of protein using bicinchoninic acid.

  1985cited by this paper
• Ultrastructure of the membrane attack complex of complement: detection of the tetramolecular C9-polymerizing complex C5b-8.

  1982cited by this paper
• Molecular organization of C9 within the membrane attack complex of complement. Induction of circular C9 polymerization by the C5b-8 assembly

  1982cited by this paper
• Blood and Marrow Neutrophils during Experimental Group B Streptococcal Infection: Quantification of the Stem Cell, Proliferative, Storage and Circulating Pools

  1982cited by this paper
• Inherited deficiency of the ninth component of complement in man.

  1980cited by this paper
• The ninth component of human complement: purification and physicochemical characterization.

  1980cited by this paper
• Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications.

  1979cited by this paper
• Interaction of E. coli strains with human serum: lack of relationship to K1 antigen.

  1976cited by this paper
• Host resistance to Serratia marcescens infection: serum bactericidal activity and phagocytosis by normal blood leukocytes.

  1976cited by this paper
• Function of the Classical and Alternate Pathways of Human Complement in Serum Treated with Ethylene Glycol Tetraacetic Acid and MgCl2-Ethylene Glycol Tetraacetic Acid

  1975cited by this paper
• Developmental aspects of complement components in the newborn. The presence of complement components and C3 proactivator (properdin factor B) in human colostrum.

  1974cited by this paper
• Mode of action of human C9: adsorption of multiple C9 molecules to cell-bound C8.

  1974cited by this paper
• Reaction mechanisms of nascent C567 (reactive lysis). II. Killing of a rough form of Escherichia coli by C567, C8, and C9.

  1974cited by this paper
• MOLECULAR ANALYSIS OF THE MEMBRANE ATTACK MECHANISM OF COMPLEMENT

  1972cited by this paper
• Human immunity to Pseudomonas aeruginosa. I. In-vitro interaction of bacteria, polymorphonuclear leukocytes, and serum factors.

  1972cited by this paper
• A plaque assay on agar for detection of gram-negative bacilli sensitive to complement.

  1972cited by this paper
• Sensitivity of serologically classified strains of escherichia coli of human origin to the serum bactericidal system.

  1970cited by this paper
• Depletion of plasma complement in vivo by a protein of cobra venom: its effect on various immunologic reactions.

  1970cited by this paper
• A STUDY OF THE RELATIONSHIP OF THE NORMAL BACTERICIDAL ACTIVITY OF HUMAN SERUM TO BACTERIAL INFECTION.

  1960cited by this paper

• Inflammatory liver diseases and susceptibility to sepsis.

  2024cites this paper
• Resolvin D1 attenuated liver injury caused by chronic ethanol and acute LPS challenge in mice

  2022cites this paper
• Rodent Models of Developmental Ischemic Stroke for Translational Research: Strengths and Weaknesses

  2019cites this paper
• Innate Immunity at Birth

  2017cites this paper
• Mechanisms of Perinatal Arterial Ischemic Stroke

  2014cites this paper
• A Conserved Virulence Plasmidic Region Contributes to the Virulence of the Multiresistant Escherichia coli Meningitis Strain S286 Belonging to Phylogenetic Group C

  2013cites this paper
• Successful pregnancy in a patient suffering from recurrent mid‐trimester miscarriage with C9 deficiency after receiving cervical cerclage followed by clindamycin and progesterone: A case report

  2012cites this paper
• The ecology of nasal colonization of Streptococcus pneumoniae, Haemophilus influenzae and Staphylococcus aureus: the role of competition and interactions with host's immune response

  2010cites this paper
• Does Inflammation after Stroke Affect the Developing Brain Differently than Adult Brain?

  2009cites this paper
• Effects of complement regulators bound to Escherichia coli K1 and Group B Streptococcus on the interaction with host cells

  2008cites this paper
• The administration of cobra venom factor reduces post-ischemic cerebral injury in adult and neonatal rats.

  2005cites this paper
• Recombinant rat IL-1beta and IL-6 synergistically enhance C3 mRNA levels and complement component C3 secretion by H-35 rat hepatoma cells.

  2005cites this paper
• C1q-Deficiency Is Neuroprotective Against Hypoxic-Ischemic Brain Injury in Neonatal Mice

  2005cites this paper
• Effects of endotoxin administration and cerebral hypoxia-ischemia on complement activity and local transcriptional regulation in neonatal rats.

  2005cites this paper
• The role of complement in neonatal hypoxic-ischemic cerebral injury.

  2004cites this paper
• Chapter 156 – Mononuclear Phagocyte System

  2004cites this paper
• The administration of complement component C9 augments post-ischemic cerebral infarction volume in neonatal rats.

  2002cites this paper
• Conservation of the modular structure of complement factor I through vertebrate evolution.

  2002cites this paper
• Neonatal syndromes of polyendocrinopathy.

  2002cites this paper
• Nonspecific Human IgG Reduces Survival in Neonatal Rats Infected with Escherichia coli

  2001cites this paper
• Complement inhibition does not reduce post-hypoxic-ischemic cerebral injury in 21-day-old rats.

  2001cites this paper
• Experimental models of Gram‐negative sepsis

  2001cites this paper
• Elevated Levels and Different Repertoire Profile of Colostral Anti‐LPS Antibodies May Have a Significant Role in Compensating Newborn Immunity

  2001cites this paper
• Modulation of the complement system in the prevention and treatment of sepsis

  2001cites this paper
• Future opportunities for nonantibiotic prevention or adjunctive therapy of neonatal bacterial infections

  1999cites this paper
• Complement component C9 enhances the capacity of beta-lactam antibiotics to kill Escherichia coli in vitro and in vivo.

  1998cites this paper